GLP-1 Side Effects: What to Expect Before, During, and After Treatment

Medically reviewed by a licensed healthcare professional. Last updated March 2026.

Key Takeaways

• Gastrointestinal symptoms (nausea, diarrhea, constipation) are the most common side effects and affect 20-44% of patients depending on the medication ^[1][2].
• Most GI side effects are dose-dependent and improve within 4-8 weeks as the body adapts.
• Serious side effects (pancreatitis, gallbladder disease) are rare, occurring in fewer than 1% of patients.
• Slow dose titration and dietary adjustments significantly reduce symptom severity.
• Always discuss new or worsening symptoms with your prescribing provider.

Understanding Why Side Effects Occur

GLP-1 receptor agonists produce weight loss by slowing gastric emptying, reducing appetite signals in the hypothalamus, and improving insulin regulation. These same mechanisms are responsible for the gastrointestinal side effects most patients experience, particularly during the initial weeks and after each dose increase ^[1].

The clinical evidence consistently shows that side effects are most pronounced during dose titration and diminish over time. In the STEP 1 trial of semaglutide, only 4.5% of participants discontinued due to gastrointestinal adverse events, despite 44% reporting nausea at some point during treatment ^[1].

Common Side Effects by Medication

Understanding the frequency of side effects helps set realistic expectations. These rates come from the pivotal clinical trials for each medication:

Semaglutide (Wegovy) — STEP 1 Trial ^[1]

Tirzepatide (Zepbound) — SURMOUNT-1 Trial ^[2]

Notably, tirzepatide shows lower reported rates of nausea and vomiting compared to semaglutide in their respective trials, though direct cross-trial comparisons have limitations. The SURMOUNT-5 head-to-head trial confirmed generally similar tolerability profiles in a direct comparison ^[3].

What to Expect During Dose Titration

Both semaglutide and tirzepatide use a gradual dose-escalation schedule designed to minimize side effects. Understanding this timeline helps patients anticipate and manage symptoms effectively.

Weeks 1-4: Starting Dose

The starting dose is intentionally low — 0.25 mg for semaglutide, 2.5 mg for tirzepatide. At these doses, side effects are mild for most patients. Common experiences include slight nausea after meals, reduced appetite (which is the intended effect), and occasional headache.

Weeks 5-16: Dose Escalation

Each dose increase may trigger a temporary return of GI symptoms. This is the phase where most patients find side effects most challenging. The standard titration schedule increases the dose every 4 weeks, but your provider can extend the interval if symptoms are difficult to manage ^[4].

Weeks 16+: Maintenance Dose

After reaching the target dose, most patients report that side effects have resolved or become manageable. The body has adapted to the medication, and eating patterns have typically adjusted to smaller portions.

Managing Common Side Effects

Nausea

Nausea is the most frequently reported side effect. Evidence-based strategies to reduce it include:

• Eating smaller, more frequent meals rather than large portions
• Avoiding high-fat, fried, or very sweet foods, which exacerbate nausea
• Eating slowly and stopping at the first sign of fullness
• Taking the injection in the evening so peak nausea occurs during sleep
• Staying hydrated with water, clear broth, or ginger tea

If nausea is severe, your provider may prescribe ondansetron (Zofran) or recommend delaying the next dose increase.

Constipation

GLP-1 medications slow gastric motility, which can cause constipation in 10-24% of patients ^[1][2]. Management strategies include:

• Gradually increasing dietary fiber (fruits, vegetables, whole grains)
• Drinking at least 64 ounces of water daily
• Daily physical activity, particularly walking
• Over-the-counter stool softeners (such as docusate) if dietary changes are insufficient — discuss with your provider first

Diarrhea

Diarrhea typically occurs in the first 1-2 weeks after a dose change and resolves on its own. If persistent, ensure adequate hydration and avoid sugar alcohols (common in sugar-free foods) which can worsen symptoms.

Rare but Serious Side Effects

These occur infrequently but require prompt medical evaluation:

Pancreatitis

Severe, persistent abdominal pain that radiates to the back, often accompanied by vomiting. Reported in fewer than 0.5% of clinical trial participants ^[4]. Seek emergency medical care immediately if you experience these symptoms.

Gallbladder Disease

Rapid weight loss — regardless of the method — increases the risk of gallstones. Symptoms include sharp pain in the upper right abdomen, particularly after fatty meals, and nausea or vomiting. The STEP trials reported cholelithiasis in approximately 1.6% of semaglutide patients versus 0.7% with placebo ^[1]. Contact your provider if you experience these symptoms.

Thyroid Concerns

GLP-1 medications carry a boxed warning regarding thyroid C-cell tumors observed in rodent studies at doses many times higher than those used in humans ^[4]. No causal link has been established in humans. Report any new neck lump, persistent hoarseness, or difficulty swallowing to your provider.

Hypoglycemia

Low blood sugar is rare in patients without diabetes. It is more likely if you are taking GLP-1 medications alongside insulin or sulfonylureas. Symptoms include shakiness, sweating, confusion, and rapid heartbeat ^[4].

When to Contact Your Provider

Contact your prescribing provider if you experience:

• Nausea or vomiting severe enough to prevent eating or drinking for more than 24 hours
• Signs of dehydration (dark urine, dizziness upon standing, dry mouth)
• Severe or worsening abdominal pain
• Symptoms that get worse rather than better over time
• Any symptom that concerns you

Seek emergency care for: Severe abdominal pain radiating to the back, difficulty breathing, facial or throat swelling, or signs of a severe allergic reaction.

The Importance of Medical Supervision

Side effect management is one of the primary reasons GLP-1 treatment should be supervised by a qualified healthcare provider. Dose adjustments, extended titration schedules, and supportive medications can make a significant difference in tolerability ^[4].

If you are currently experiencing side effects or are concerned about starting GLP-1 therapy, find a GLP-1 clinic near you that provides ongoing monitoring and side effect support. You can also explore telehealth options for convenient access to provider guidance between visits.

---

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Individual results vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you are experiencing a medical emergency, call 911.

Sources

1. Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)." New England Journal of Medicine. 2021;384:989-1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
2. Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)." New England Journal of Medicine. 2022;387:205-216. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
3. Aronne LJ, et al. "Tirzepatide vs Semaglutide for Weight Loss in Adults with Obesity (SURMOUNT-5)." ClinicalTrials.gov NCT05822609. https://clinicaltrials.gov/study/NCT05822609
4. FDA. Wegovy Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
5. FDA. Zepbound Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf
6. NIH National Institute of Diabetes and Digestive and Kidney Diseases. "Prescription Medications to Treat Overweight & Obesity." https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity